AbbVie Receives CHMP Positive Opinion For Skyrizi For Moderate To Severe Crohn’s Disease
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – AbbVie Inc. (ABBV) said on Monday that the Committee for Medicinal Products for Human Use has adopted positive opinion to extend the indication of Skyrizi for the treatment of adults with moderate to severe Crohn’s Disease in the European Union.
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1456116350-d0e3eae0adb44c35a6ee5bcdb7fb1725.jpg "A Primer on Philanthropic Vehicles")
